kallikrein

DRUG2 trials

Sponsors

Techpool Bio-Pharma Co., Ltd., The Second Hospital of Hebei Medical University

Conditions

Cerebral InfarctionStroke, Acute

Phase 4

The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein

Techpool Bio-Pharma Co., Ltd.Cerebral Infarction

Start: 2015-08-31End: 2018-11-30Target: 2186Updated: 2018-01-17

Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients

CompletedNCT04102956

The Second Hospital of Hebei Medical UniversityStroke, Acute

Start: 2017-07-01End: 2019-08-25Updated: 2021-03-01

Related Papers

Protective effects of human urinary kallidinogenase against corticospinal tract damage in acute ischemic stroke patients

Neuroreport2024-03-123 citations

Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients.

2017-03-0611 citations